Pharmacological advances in the treatment of neuro-otological and eye movement disorders

Current Opinion in Neurology

Volumn 19, Issue 1, 2006, Pages 33-40

  Strupp, Michael ^a,b   Brandt, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Aminopyridines; Bilateral vestibulopathy; Downbeat nystagmus; Episodic ataxia type 2; M ni re's disease; Ocular flutter; Opsoclonus; Periodic alternating nystagmus; Upbeat nystagmus; Vestibular migraine; Vestibular neuritis

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ACETAZOLAMIDE; AMINOPYRIDINE DERIVATIVE; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAHISTINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CLONAZEPAM; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; GABAPENTIN; GENTAMICIN; HISTAMINE AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; LAMOTRIGINE; METHYLPREDNISOLONE; METOPROLOL; POTASSIUM CHANNEL BLOCKING AGENT; PROPANOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALACICLOVIR; VALPROIC ACID; ZOLMITRIPTAN;

ARNOLD CHIARI MALFORMATION; AUTOSOMAL DOMINANT DISORDER; B LYMPHOCYTE; BENIGN PAROXYSMAL POSITIONAL VERTIGO; BRAIN INFARCTION; BRAIN STEM; CD8+ T LYMPHOCYTE; CEREBELLAR ATAXIA; CEREBELLUM; CEREBELLUM ATROPHY; CEREBELLUM DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENDOLYMPH; EVOKED OTOACOUSTIC EMISSION; EYE MOVEMENT DISORDER; FLUID INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAIT DISORDER; GENE MUTATION; HERPES SIMPLEX VIRUS 1; HUMAN; MENIERE DISEASE; META ANALYSIS; MIGRAINE; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NYSTAGMUS; OPSOCLONUS; PAIN; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PURKINJE CELL; REVIEW; SALT INTAKE; SODIUM RESTRICTION; STRIA VASCULARIS; SYSTEMATIC REVIEW; VERTIGO; VESTIBULAR DISORDER; VESTIBULAR FUNCTION; VESTIBULAR NEURONITIS; VISUAL DISORDER; VOMITING;

EID: 31644433924     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000196156.00481.e1     Document Type: Review

References (68)

1. Brandt T, Dieterich M, Strupp M. Vertigo and dizziness - common complaints. London: Springer, 2005. Short clinically oriented text book on the diagnosis and current treatment of vestibular disorders with a DVD.
2. Sekitani T, Imate Y, Noguchi T, Inokuma T. Vestibular neuronitis: epidemiological survey by questionnaire in Japan. Acta Otolaryngol (Stockh) Suppl 1993; 503:9-12.
3. Schulz P, Arbusow V, Strupp M, et al. Highly variable distribution of HSV-1-specific DNA in human geniculate, vestibular and spiral ganglia. Neurosci Lett 1998; 252:139-142.
4. Arbusow V, Schulz P, Strupp M, et al. Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol 1999; 46:416-419.
5. Arbusow V, Theil D, Strupp M, et al. HSV-1 not only in human vestibular ganglia but also in the vestibular labyrinth. Audiol Neuro Otol 2000; 6:259-262.
6. Theil D, Arbusow V, Derfuss T, et al. Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. Brain Pathol 2000; 11:408-413.
7. Theil D, Derfuss T, Strupp M, et al. Cranial nerve palsies: herpes simplex virus type 1 and varizella-zoster virus latency. Ann Neurol 2002; 51:273-274.
8. Theil D, Derfuss T, Paripovic I, et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003; 163:2179-2184.
9. Kitahara T, Kondoh K, Morihana T, et al. Steroid effects on vestibular compensation in human. Neurol Res 2003; 25:287-291.
10. Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004; 351:354-361. State-of-the-art prospective, randomized, placebo-controlled trial that demonstrates that corticosteroids improve the recovery of peripheral vestibular function in vestibular neuritis.
11. Minor LB, Schessel DA, Carey JP. Ménière's disease. Curr Opin Neurol 2004; 17:9-16.
12. Yeh TH, Herman P, Tsai MC, et al. A cationic nonselective stretch-activated channel in the Reissner's membrane of the guinea pig cochlea. Am J Physiol 1998; 274:C566-C576.
13. van-Deelen GW, Huizing EH. Use of a diuretic (Dyazide) in the treatment of Ménière's disease. A double-blind cross-over placebo-controlled study. ORL J Otorhinolaryngol Relat Spec 1986; 48:287-292.
14. Smith WK, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. J Laryngol Otol 2005; 119:102-105. Important epidemiological survey on the different ways to treat Ménière's disease in the UK.
15. Magnusson M, Padoan S, Karlberg M, Johansson R. Delayed onset of ototoxic effects of gentamicin in patients with Ménière's disease. Acta Otolaryngol (Stockh) Suppl 1991; 485:120-122.
16. Lange G, Maurer J, Mann W. Long-term results after interval therapy with intratympanic gentamicin for Ménière's disease. Laryngoscope 2004; 114:102-105. Although not controlled or blinded, an interesting long-term study showing promising effects of intratympanic gentamicin therapy. This trial was performed by one of the pioneers of the treatment of Ménière's disease with intratympanic gentamicin (G.L.).
17. Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Ménière's disease: a meta-analysis. Laryngoscope 2004; 114:2085-2091.
18. Carey JP, Hirvonen T, Peng GC, et al. Changes in the angular vestibulo-ocular reflex after a single dose of intratympanic gentamicin for Ménière's disease. Ann NY Acad Sci 2002; 956:581-584.
19. Barrs DM. Intratympanic injections of dexamethasone for long-term control of vertigo. Laryngoscope 2004; 114:1910-1914.
20. Yilmaz I, Yilmazer C, Erkan AN, et al. Intratympanic dexamethasone injection effects on transient-evoked otoacoustic emission. Am J Otolaryngol 2005; 26:113-117.
21. Claes J, Van-de-Heyning PH. Medical treatment of Ménière's disease: a review of literature. Acta Otolaryngol (Stockh) Suppl 1997; 526:37-42.
22. James A, Thorp M. Ménière's disease. Clin Evid 2004; 742-750. Up-to-date overview on the actual treatment options for Ménière's disease.
23. Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999; 120:400-405.
24. Brandt T, Dieterich M. Vestibular paroxysmia: vascular compression of the eighth nerve? Lancet 1994; 343:798-799.
25. Brandt T, Schautzer F, Hamilton D, et al. Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain 2005; 128:1579-1589. First description of spatial memory and navigation deficits as well as hippocampal atrophy in patients with bilateral vestibular failure due to neurofibromatosis 2.
26. Arbusow V, Strupp M, Dieterich M, et al. Serum antibodies against membrainous labyrinth in patients with 'idiopathic' bilateral vestibulopathy. J Neurol 1998; 245:132-136.
27. Ågrup C, Keir G, Thompson EJ, Bronstein AM. Systemic autoantibodies against discrete inner ear compartments in bilateral vestibular loss. Neurology 2005; 65:167. The authors confirm and extend previous findings [26] on specific autoantibodies against inner ear structures in certain patients with bilateral vestibular failure.
28. Deutschlander A, Glaser M, Strupp M, et al. Steroid treatment in bilateral vestibulopathy with inner ear antibodies. Acta Otolaryngol (Stockh) 2005; 125:848-851.
29. von-Brevern M, Zeise D, Neuhauser H, et al. Acute migrainous vertigo: clinical and oculographic findings. Brain 2005; 128:365-374. Excellent and carefully performed study which gives new insights into the pathophysiology of vestibular migraine.
30. Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 2004; 24:83-91.
31. Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol 2003; 16:5-13.
32. Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 2002; 23:364-371.
33. Neuhauser H, Radtke A, von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: A pilot randomized placebo-controlled trial. Neurology 2003; 60:882-883.
34. Carmona S, Settecase N, Majkowski J, et al. Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. Ann NY Acad Sci 2005; 1039:517-520.
35. Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2004; 2:103-108.
36. Griggs RC, Nutt JG. Episodic ataxias as channelopathies. Ann Neurol 1995; 37:285-287.
37. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17-22. Very important clinical and neurogenetic study.
38. Griggs RC, Moxley RT, Lafrance RA, McQuillen J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 1978; 28:1259-1264.
39. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543-552.
40. Kullmann DM. The neuronal channelopathies. Brain 2002; 125:1177-1195.
41. Etzion Y, Grossman Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 2001; 139:419-425.
42. Strupp M, Kalla R, Dichgans M, et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62:1623-1625. New approach for treating EA2 in patients who do not respond to acetazolamide. However, the number of patients is so far quite small. Findings have to be confirmed in a larger placebo-controlled.
43. Weisz CJ, Raike RS, Soria-Jasso LE, Hess EJ. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J Neurosci 2005; 25:4141-4145. Elegant animal study that convincingly shows aminopyridines prevent attacks in calcium-channel mutations. It further evaluates the underlying pharmacological mechanism involved in the blocking of different potassium channels.
44. Kalla R, Deutschlander A, Hufner K et al. Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology (in press). First description of a hypofunction of the flocculus in patients with downbeat nystagmus.
45. Marti S, Straumann D, Glasauer S. The origin of downbeat nystagmus: an asymmetry in the distribution of on-directions of vertical gaze-velocity purkinje cells. Ann NY Acad Sci 2005; 1039:548-553. Elegant new hypothesis on the pathophysiology of downbeat and upbeat nystagmus which is meanwhile supported by other findings.
46. Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope 2001; 111:1490-1493.
47. Currie JN, Matsuo V. The use of clonazepam in the treatment of nystagmus-induced oscillopsia. Ophthalmology 1986; 93:924-932.
48. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997; 41:818-825.
49. Strupp M, Schuler O, Krafczyk S, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61:165-170.
50. Helmchen C, Sprenger A, Rambold H, et al. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus. Neurology 2004; 63:752-753.
51. Sprenger A, Zils E, Rambold H, et al. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus. Ann NY Acad Sci 2005; 1039:395-403.
52. Kalla R, Glasauer S, Schautzer F, et al. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology 2004; 62:1228-1229.
53. Ances BM, Dalmau JO, Tsai J, et al. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. Am J Ophthalmol 2005; 140:142-144.
54. Dieterich M, Straube A, Brandt T, et al. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 1991; 54:627-632.
55. Glasauer S, Kalla R, Buttner U, et al. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J Neurol Neurosurg Psychiatry 2005; 76:451-453.
56. Stahl JS, Plant GT, Leigh RJ. Medical treatment of nystagmus and its visual consequences. J R Soc Med 2002; 95:235-237.
57. Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry 2003; 74:1-4.
58. Straube A, Leigh RJ, Bronstein A, et al. EFNS task force - therapy of nystagmus and oscillopsia. Eur J Neurol 2004; 11:83-89. Excellent review by the leading experts in this field.
59. Straube A. Nystagmus: an update on treatment in adults. Expert Opin Pharmacother 2005; 6:583-590.
60. Straube A. Pharmacology of vertigo/nystagmus/oscillopsia. Curr Opin Neurol 2005; 18:11-14.
61. Herishanu Y, Louzoun Z. Trihexyphenidyl treatment of vertical pendular nystagmus. Neurology 1986; 36:82-84.
62. Jabbari B, Rosenberg M, Scherokman B, et al. Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction. Mov Disord 1987; 2:93-98.
63. Leigh RJ, Burnstine TH, Ruff RL, Kasmer RJ. Effect of anticholinergic agents upon acquired nystagmus: A double blind-study of trihexyphenidyl and tridehexethyl chloride. Neurology 1991; 41:1737-1741.
64. Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1997; 244:9-16.
65. Leigh RJ, Tomsak RL, Grant MP, et al. Effectiveness of botulinum toxin administered to abolish acquired nystagmus. Ann Neurol 1992; 32:633-642.
66. Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin - an effective treatment for acquired nystagmus with oscillopsia. Eye 2002; 16:804-806.
67. Tomsak RL, Remler BF, verbuch-Heller L, et al. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol 1995; 119:489-496.
68. Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005; 115:115-119.